Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome.

Abstract

BACKGROUND:

Endostatin, a C-terminal fragment of collagen XVIII, is an endogenous angiogenesis inhibitor. While endostatin is being investigated for its usefulness in treating solid tumors, its significance in hematologic malignancies is unknown.

METHODS:

The authors evaluated plasma endostatin (PE) levels using an enzyme linked immunoassay in 71 patients with acute myeloid leukemia (AML) and 43 patients with myelodysplastic syndrome (MDS), and correlated PE with various clinical parameters.

RESULTS:

There was no significant difference in the median PE level between AML/MDS patients and the normal controls. Nevertheless, patients who achieved complete remission (CR) had a significantly lower median PE level compared to those who did not. In multivariate analysis, PE was found to be a significant (P = 0.03) predictor of overall survival (OS) with adjustment of the other baseline covariates, including patient age, history of antecedent hematologic disorders, and the use of protective environments. The prognostic value of PE was also evaluated by dividing MDS/AML patients into high and low PE groups using the median PE level of normal controls as the cut-off. The authors found that patients in the high PE group survived for a significantly shorter time than those patients in the low PE group.

CONCLUSIONS:

PE is a useful prognostic predictor of CR and OS for AML/MDS patients. The mechanism underlying the association between high PE and poor clinical outcome is unclear, although it may be related to the possible PE reflection of tumor burden.

• Authors: Raymond Lai, Elihu Estey, Yu Shen, Simona Despa, Hagop Kantarjian, Miloslav Beran, Taghi Maushouri, Robert C Quackenbuch, Micheal Keating, Maher Albitar
• Journal: Cancer (Cancer) Vol. 94 Issue 1 Pg. 14-7 (Jan 01 2002) ISSN: 0008-543X [Print] United States
• PMID: 11815955 (Publication Type: Journal Article)
• Copyright: Copyright 2002 American Cancer Society.

Chemical References

• Antineoplastic Agents
• Collagen Type XVIII
• Endostatins
• Peptide Fragments
• Collagen

Topics

• Acute Disease
• Antineoplastic Agents (therapeutic use)
• Collagen (blood)
• Collagen Type XVIII
• Endostatins
• Enzyme-Linked Immunosorbent Assay
• Humans
• Leukemia, Myeloid (blood, drug therapy)
• Myelodysplastic Syndromes (blood, drug therapy)
• Peptide Fragments (blood)
• Prognosis
• Proportional Hazards Models
• Remission Induction
• Survival Analysis